|
US2008292710A1
|
|
Liquid Dosage Forms Of Acid Labile Drugs
|
|
WO2009061529A1
|
|
(+)-enantiomer of 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazole and processing method eor preparing the same
|
|
US2009042887A1
|
|
Methods for Preventing or Reducing the Number of Gout Flares Using Xanthine Oxidoreductase Inhibitors and Anti-Inflammatory Agents
|
|
WO2008083319A1
|
|
Solid state forms of enantiopure ilaprazole
|
|
WO2008055112A2
|
|
Methods of treating autism and autism spectrum disorders
|
|
CN101426371A
|
|
Pharmaceutical compositions of ilaprazole
|
|
WO2007062028A2
|
|
Treatment of qt interval prolongation and diseases associated therewith
|
|
CA2607953A1
|
|
Methods for treating nephrolithiasis
|
|
CA2580533A1
|
|
Methods of treating disorders having a component of mercury toxicity
|
|
EP1768668A2
|
|
Multiple ppi dosage form
|
|
EP1748794A2
|
|
Sequential sprm/progestin treatment
|
|
US2005113337A1
|
|
Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
|
|
US2007244037A1
|
|
Human Chemokine HCC-1 Polypeptides To Improve Stem Cell Transplantation
|
|
CA2519920A1
|
|
Use of chemokine receptor agonists for stem cell transplantation
|
|
WO2004060489A2
|
|
Treatment of chronic heart failure
|
|
MXPA05006629A
|
|
Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer.
|
|
EP1569655A1
|
|
Use of selective progesterone receptor modulators for the treatment of androgen deficiency
|
|
EP1490091A1
|
|
Enhancement of endogenous gonadotropin production
|
|
US6827208B2
|
|
Packaging system for separately storing and dispensing together separate medication components
|
|
WO02094183A2
|
|
A method for tumor treatment with fumagillol derivatives
|
